1-800-710-4674

Find a Doctor

Return to Physician Search

Physician Profile

 
Barriger Robert (Bryan) MD - OHC Medical Oncologist

R. Bryan Barriger, M.D.

“I treat each person the way I would like to see my family be treated. I combine compassion and expertise in new radiation technologies to deliver the most appropriate and effective treatments. Being part of a person's journey through cancer treatment and making a difference during a critical time in their life is humbling and rewarding. ”
Learn More.

Practices

Radiation Oncology

Locations

Hamilton
Springfield

Request
appointment

or call
1-800-710-4674

SPECIALTIES

Targeted radiation therapy
Stereotactic radiosurgery (brain)
Stereotactic body radiation therapy (lung, liver, spine)
Intensity-modulated radiation therapy
3-D conformal radiation therapy

MEDICAL INTERESTS

Thoracic oncology (lung and esophageal tumors)
Breast cancer
Prostate cancer
Head and neck cancer

PERSONAL INTERESTS

Spending time with family, playing golf, and cycling.

MEDICAL SCHOOL

Indiana University School of Medicine

RESIDENCY

Indiana University School of Medicine, Radiation Oncology

INTERNSHIP

Indiana University School of Medicine, Internal Medicine

CERTIFICATIONS & LICENSURES

American Board of Radiology
Indiana State Medical Board
Kentucky State Medical Board
Ohio State Medical Board

MEMBERSHIPS

American College of Radiology
American Radium Society
American Society of Therapeutic Radiation and Oncology (ASTRO)

COMMITTEES

Chair, Radiation Oncology Program, American Institute of Radiologic Pathology
Co-chair, Radiation Oncology Esophageal and Lung committees for the Via Oncology Pathways Physician Advisory Committee

Stanic S, Paulus R, Timmerman RD, Michalski J, Barriger RB, Bezjak A, Videtic GM, Bradley J. No clinically significant changes in pulmonary function following stereotactic body radiation therapy (SBRT) among medically inoperable patients with early stage peripheral non-small cell lung cancer: An analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014 Apr 1:88(5):1092-9. PMID: 24661663.

Palma DA, Senan S, Oberije C, Belderbos J, Rodriguez de Dios N, Bradley JD, Barriger RB, Moreno M, Kim TH, Ramella S, Ball D, Rengan R, Marks LB, de Ruyck K, Warner A, Rodrigues G. Predicting esophagitis after chemoradiotherapy for non-small cell lung cancer: An individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013 Nov 15:87(4):690-6. PMID: 24035329.

Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, Belani C, DeLuca J, Recht A, Maheshwari N, Barriger R, Yao A, DeCamp M. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer 2013 Aug 1:199(15):2683-91. PMID: 23605504.

Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradly JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013 Feb 1:85(2):444-50. PMID: 22682812.

Barriger RB, Forquer JA, Henderson MA, Johnstone PAS, Fakiris AJ. A dose-volume analysis of radiation pneumonitis in nonsmall cell lung cancer patients treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2012 Jan 1:82(1):457-62. PMID: 21035956.

Andolino DL, Forquer JA, Henderson MA, Barriger RB, Shapiro RH, Brabham JG, Johnstone PA, Cardenes HR, Fakiris AJ. Chest wall toxicity following stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011 Jul 1;80(3):692-7. PMID: 21288656.

Barriger RB, Chang A, Lo SS, Timmerman RD, DesRosiers C, Boaz JC, Fakiris AJ. Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother Oncol 2011 Feb:98(2):207-12. PMID:21269713.

Barriger RB, McGarry RC, Johnstone PAS, Fakiris AJ. Dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010 Dec:1;78(5):1381-6. PMID: 20231061.

Barriger RB and Johnstone PAS. Advanced radiation technology in the treatment of anal cancer. Oncology 2009:23(12):1096-1098. PMID: 20017293.

Barriger RB, Calley C, Cardenes HR. Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol 2009 Sep:11(9):609-14. PMID: 19776001.

Book Chapters

Barriger RB. Radiation pneumonitis: Prediction and management. In: Lo S, Teh BS, Mayr NA, Machtay M. Stereotactic Body Radiation Therapy: Lung Cancer. London, UK: Future Medicine Ltd; 2013:89-108.

Barriger RB. Chest wall toxicities: Prediction and management. In: Lo S, Teh BS, Mayr NA, Machtay M. Stereotactic Body Radiation Therapy: Lung Cancer. London, UK: Future Medicine Ltd; 2013:109-128.

As a member of our OHC physician team, Dr. Barriger has full access to the OHC Clinical Trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

You and your physician have the support of the most exceptional care team which includes OHC physician colleagues, advanced clinical practitioners, treatment nurses, research nurses, pharmacists, medical assistants, clinical coordinators, receptionists and schedulers, patient account services representatives, nurse and financial navigators, call center representatives, business and clinical practice managers, and volunteers.